Ertugliflozin/sitagliptin

Drug Profile

Ertugliflozin/sitagliptin

Alternative Names: MK 8835/MK 0431; MK 8835A

Latest Information Update: 03 Nov 2016

Price : $50

At a glance

  • Originator Merck & Co; Pfizer
  • Class Antihyperglycaemics; Chlorobenzenes; Glycosides; Heterocyclic bicyclo compounds; Phenyl ethers; Pyrazines; Small molecules; Triazoles
  • Mechanism of Action CD26 antigen inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Type 2 diabetes mellitus

Most Recent Events

  • 01 Nov 2016 Merck and Pfizer announce intention to submit regulatory applications outside USA by 2017
  • 11 Jun 2016 Adverse events and efficacy data from the phase III VERTIS Factorial trial released by Merck and Pfizer
  • 09 Jun 2016 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top